|29th January 2021||Beth Hecht||150,000||Grant/award etc.||$0.00|
|30th June 2020||Beth Hecht||3,731||Grant/award etc.||$2.26||$8,432.06|
|10th June 2020||Beth Hecht||23,453||Grant/award etc.||$0.00|
|10th June 2020||Gregory J Robitaille||23,453||Grant/award etc.||$0.00|
|10th June 2020||James A. Jr. Robinson||23,453||Grant/award etc.||$0.00|
|10th June 2020||John P. Schmid||23,453||Grant/award etc.||$0.00|
|10th June 2020||Bryant Fong||23,453||Grant/award etc.||$0.00|
|10th June 2020||Alan L Heller||23,453||Grant/award etc.||$0.00|
|10th June 2020||Linda M Szyper||23,453||Grant/award etc.||$0.00|
|13th March 2020||Beth Hecht||4,000||Open or private purchase||$1.97||$7,880.00|
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 10/10.
Neos Therapeutics, Inc is a pharmaceutical company focused on developing, manufacturing and commercializing products. The firm manufactures and markets its generic version of the branded product Tussionex. The company was founded by Darlene R. Ryan on November 30, 1994 and is headquartered in Grand Prairie, TX.